Outlook Therapeutics, Inc. (OTLK)

Market Cap	44.82M
Revenue (ttm)	n/a
Net Income (ttm)	-46.81M
Shares Out	32.02M
EPS (ttm)	-2.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	417,428
Open	1.490
Previous Close	1.495
Day's Range	1.360 - 1.495
52-Week Range	0.870 - 12.850
Beta	0.54
Analysts	Strong Buy
Price Target	10.20 (+628.57%)
Earnings Date	May 14, 2025

About OTLK

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and change...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 13, 2016
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: OTLK
• Website: https://www.outlooktherapeutics.com

Analyst Forecast

According to 5 analysts, the average rating for OTLK stock is "Strong Buy." The 12-month stock price forecast is $10.2, which is an increase of 628.57% from the latest price.

Price Target

$10.2

(628.57% upside)

Analyst Consensus: Strong Buy